These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 25523099

  • 1. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK, Lee KS, Lee DK, Lee SY, Chang HY, Choi J, Lee JI.
    Exp Mol Med; 2014 Dec 19; 46(12):e127. PubMed ID: 25523099
    [Abstract] [Full Text] [Related]

  • 2. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J, Hong W, Yao KN, Zhu XH, Chen ZY, Ye L.
    World J Gastroenterol; 2019 Mar 28; 25(12):1492-1501. PubMed ID: 30948912
    [Abstract] [Full Text] [Related]

  • 3. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S.
    Metabolism; 2012 Jul 28; 61(7):944-53. PubMed ID: 22154323
    [Abstract] [Full Text] [Related]

  • 4. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A, Liebisch G, Okun JG, Chamulitrat W, Schmitz G, Stremmel W.
    Eur J Clin Invest; 2015 Sep 28; 45(9):925-31. PubMed ID: 26108973
    [Abstract] [Full Text] [Related]

  • 5. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
    Ozel Coskun BD, Yucesoy M, Gursoy S, Baskol M, Yurci A, Yagbasan A, Doğan S, Baskol G.
    Eur J Gastroenterol Hepatol; 2015 Feb 28; 27(2):142-9. PubMed ID: 25533429
    [Abstract] [Full Text] [Related]

  • 6. N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice.
    Kim JK, Cho SM, Kang SH, Kim E, Yi H, Yun ES, Lee DG, Cho HJ, Paik YH, Choi YK, Haam SJ, Shin HC, Lee DK.
    J Gastroenterol Hepatol; 2012 Nov 28; 27(11):1745-51. PubMed ID: 22849613
    [Abstract] [Full Text] [Related]

  • 7. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W.
    Hepatology; 2012 May 28; 55(5):1369-78. PubMed ID: 22183915
    [Abstract] [Full Text] [Related]

  • 8. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
    Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H.
    J Gastroenterol; 2016 Feb 28; 51(2):162-72. PubMed ID: 26190501
    [Abstract] [Full Text] [Related]

  • 9. Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.
    Valenzuela R, Echeverria F, Ortiz M, Rincón-Cervera MÁ, Espinosa A, Hernandez-Rodas MC, Illesca P, Valenzuela A, Videla LA.
    Lipids Health Dis; 2017 Apr 11; 16(1):64. PubMed ID: 28395666
    [Abstract] [Full Text] [Related]

  • 10. A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis.
    Li H, Wang M, Chen P, Zhu M, Chen L.
    Biomed Pharmacother; 2024 May 11; 174():116617. PubMed ID: 38643542
    [Abstract] [Full Text] [Related]

  • 11. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
    Fan JG, Zhong L, Tia LY, Xu ZJ, Li MS, Wang GL.
    World J Gastroenterol; 2005 Apr 21; 11(15):2346-50. PubMed ID: 15818751
    [Abstract] [Full Text] [Related]

  • 12. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct 21; 1864(10):1422-1437. PubMed ID: 31325638
    [Abstract] [Full Text] [Related]

  • 13. Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling.
    Xu F, Wang J, Wang P, Hou T, Zhou H, Zhao Y, Wang J, Liu Y, Liang X.
    Eur J Pharmacol; 2022 Feb 15; 917():174760. PubMed ID: 35033554
    [Abstract] [Full Text] [Related]

  • 14. Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c.
    Dossi CG, Tapia GS, Espinosa A, Videla LA, D'Espessailles A.
    J Nutr Biochem; 2014 Sep 15; 25(9):977-84. PubMed ID: 24993917
    [Abstract] [Full Text] [Related]

  • 15. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
    Nozaki Y, Fujita K, Wada K, Yoneda M, Kessoku T, Shinohara Y, Imajo K, Ogawa Y, Nakamuta M, Saito S, Masaki N, Nagashima Y, Terauchi Y, Nakajima A.
    BMC Gastroenterol; 2015 Apr 01; 15():42. PubMed ID: 25881230
    [Abstract] [Full Text] [Related]

  • 16. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
    Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ.
    Liver Int; 2015 Mar 01; 35(3):953-66. PubMed ID: 24750664
    [Abstract] [Full Text] [Related]

  • 17. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
    Ali MH, Messiha BA, Abdel-Latif HA.
    Pharm Biol; 2016 Jul 01; 54(7):1198-208. PubMed ID: 26134756
    [Abstract] [Full Text] [Related]

  • 18. Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model.
    Comeglio P, Sarchielli E, Filippi S, Cellai I, Guarnieri G, Morelli A, Rastrelli G, Maseroli E, Cipriani S, Mello T, Galli A, Bruno BJ, Kim K, Vangara K, Papangkorn K, Chidambaram N, Patel MV, Maggi M, Vignozzi L.
    J Endocrinol Invest; 2021 Oct 01; 44(10):2175-2193. PubMed ID: 33586025
    [Abstract] [Full Text] [Related]

  • 19. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
    Cha JY, Park JM, Lee HJ, Bae JS, Han YM, Oh BC, Ko KH, Hahm KB.
    Curr Pharm Des; 2017 Oct 01; 23(27):3941-3951. PubMed ID: 28714405
    [Abstract] [Full Text] [Related]

  • 20. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.
    Honda T, Ishigami M, Luo F, Lingyun M, Ishizu Y, Kuzuya T, Hayashi K, Nakano I, Ishikawa T, Feng GG, Katano Y, Kohama T, Kitaura Y, Shimomura Y, Goto H, Hirooka Y.
    Metabolism; 2017 Apr 01; 69():177-187. PubMed ID: 28285648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.